by GAtherton | Jul 22, 2019 | Latest research news
Amphotericin B (AmB) is the drug of choice for the treatment of many fungal infections. Despite this, the drug can cause several serious side effects, one of which being nephrotoxicity (toxicity to the kidneys). Conventional AmB can be adapted into a lipid...
by GAtherton | Jul 19, 2019 | Latest research news
A new screening test kit will speed up diagnosis of chronic pulmonary aspergillosis (CPA) say researchers from the University of Manchester. The test, available commercially from LDBio diagnostics, is very simple and needs no power source or equipment and therefore is...
by GAtherton | Jun 5, 2019 | Latest research news
The current issue of the European Respiratory Society’s journal, Breathe, focuses on living well with a chronic respiratory disease, and includes an article from an ABPA patient. Links to this patient voice article, and other pieces which may be of interest to...
by GAtherton | May 21, 2019 | Latest research news
In the last years clinicians and researchers have realised that the interactions between microorganisms in polymicrobial infections (when a single patient is colonised/infected with two or more pathogens) are relevant for the progression of the disease. Contacts...
by GAtherton | Apr 4, 2019 | Latest research news
A new study from the Netherlands has challenged the widely held opinion that airborne transmission of Aspergillus fumigatus between patients with cystic fibrosis (CF) does not occur. Chronic Pulmonary Aspergillosis (CPA) is a chronic condition affecting...
by GAtherton | Mar 25, 2019 | Latest research news
A recently published research paper suggests that Posaconazole works better than itraconazole and voriconazole against allergic bronchopulmonary aspergillosis (ABPA) in patients with Cystic Fibrosis. ABPA patients tend to have a hypersensitive response to Aspergillus...